The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Advice for physicians when selecting patients with CLL for treatment with BTK inhibitors
Catherine Coombs, MD, UCI Health, Orange, CA, underlines the factors physicians should consider when selecting patients with chronic lymphocytic leukemia (CLL) for treatment with BTK inhibitors. Dr Coombs encourages physicians to consider the patient’s risk for toxicity, specifically focusing on cardiac risk, and suggests tests physicians can conduct to explore this. She suggests patients with high-risk profiles should use alternative therapies such as venetoclax. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
